Ignite Creation Date:
2024-05-05 @ 11:51 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00150462
Status:
COMPLETED
Last Update Posted:
2017-05-02
First Post:
2005-09-06
Brief Title:
Safety Study of the Proteasome Inhibitor PR-171 Carfilzomib for Injection in Patients With Hematological Malignancies
Sponsor:
Amgen
Organization:
Amgen
Study Overview
Official Title:
A Phase I Study of the Safety and Pharmacokinetics of Escalating Intravenous Doses of the Proteasome Inhibitor PR-171 in Patients With Hematological Malignancies
Status:
COMPLETED
Status Verified Date:
2017-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to test the safety and tolerability of carfilzomib at different dose levels on hematological cancers such as multiple myeloma non-Hodgkins lymphoma Hodgkins disease or Waldenstroms macroglobulinemia Carfilzomib is a proteasome inhibitor an enzyme responsible for degrading a wide variety of cellular proteins
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None